Novel Rx
2 years 5 months ago
Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed vedolizumab and belimumab were associated with higher CMs. Vedolizumab showed specific CM pattern (corpus collosum agenesis).
@RheumNow #EULAR2022 ABST#OP0129 https://t.co/wgRlm9QLgW
2 years 5 months ago
No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest.
@RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
2 years 5 months ago
#EULAR2022 OP0138:
BIOBADASER registry:
Cancer risk in AI disease after bDMARD & tsDMARD + h/o prior malignancy
⭐️352 pts w prior malignancy in registry, 32 developed a 2nd incident malignancy
27 rate of cancer/1000 patient years. No diff of cancer or mortality b/w Rx
@Rheumnow https://t.co/nTuUooBmzV
2 years 5 months ago
#EULAR2022 ASAS/EULAR AxSpA Recs
⭐️Last: 2016
▶️All: education, exercise, 🚭
▶️❌csDMARD for axial disease
▶️TNF/IL17 (or JAK) with high disease: ASDAS>/=2.1
▶️Monoclonal TNF for uveitis/IBD, high PsO: IL-17
▶️Sustained remission: tapering of bDMARD "can be considered"
@RheumNow https://t.co/3yYU0Vb37r
2 years 5 months ago
OP0129 Eudravigilance eval pregnancies exposed to non-TNF biologics compared certolizumab. Possible signal w/#vendolizumab: 3 cases of corpus callosum agenesis (2 Crohn’s, 1 UC, 2 assc w/ other CNS malformations). Belim did not show consistent pattern #EULAR2022 @rheumnow https://t.co/BNKaxu6G0c
2 years 5 months ago
New #SLE drug to pay attention to!
iberdomide target Ikaros and Aiolos, reduce B cell, reduce autoAb and reduce IFN sig while enhancing regulatory T cells- Prof T Dorner #EULAR2022 @rheumnow https://t.co/q39pxK3gFJ
2 years 5 months ago
Spanish safety registry BIOBADASER 3.0:
*9000+ pts with IMID treated w/ bio or tsDMARDS
*352 pts w/ prior malignancy
*32 incident malignancies
-> 27 events/1000PY
NO diff between ttmts in incidence or mortality but low number pts in non TNFi groups
@RheumNow #EULAR2022
OP0138 https://t.co/8IyC6NdGCF
2 years 5 months ago
#ClinicalPearl #SLE Rx tomorrow? Combine #Ritux+#Belimumab variable response, CART Rx for severe refractory #lupus, antiCD38i, drugs i. RCTs=hope for pts. #EULAR2022 T Dorner @RheumNow @eular_org https://t.co/2BReU5bhG0
2 years 5 months ago
ANCA vasculitis guidelines make sense. Less use of cyclophosphamide was already the case, rituximab can be for induction & maintenance, I am reluctant though in severe disease to stop maintenance Rx at 1 or 2 yrs and go longer as at least 1/3 will relapse beyond 2 yrs. @RheumNow https://t.co/3xRHWya2Uq